Synageva BioPharma (GEVA) Issued U.S. Patent For Treatment Of LAL Deficiency
3/4/2014 6:46:50 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced that the U.S. Patent and Trademark Office today issued U.S. Patent No. 8,663,631 covering methods of treating lysosomal acid lipase deficiency (LAL Deficiency). This patent provides protection until 2031, not including any patent term extension. The patent complements Synageva’s existing and planned global patent portfolio covering its LAL Deficiency program, which includes intellectual property directed to composition of matter, methods of use, and manufacturing.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by